- Home
- MIST vs ALEC Comparison
MIST vs ALEC Comparison
Compare MIST & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | ALEC |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 200.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MIST | ALEC |
|---|---|---|
| Price | $1.95 | $1.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 7 |
| Target Price | ★ $8.50 | $3.33 |
| AVG Volume (30 Days) | ★ 3.4M | 1.0M |
| Earning Date | 03-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,048,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.26 |
| 52 Week Low | $0.63 | $0.87 |
| 52 Week High | $3.06 | $3.40 |
Technical Indicators
Market Signals| Indicator | MIST | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 69.62 |
| Support Level | $1.97 | $1.77 |
| Resistance Level | $2.06 | $2.00 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 18.75 | 85.57 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.